How would you approach treatment for a pre-menopausal patient with PR-positive, ER-negative, HER2-negative cT1c N1 breast cancer?

The prevalence of ER- PR+ HER2- breast cancer is relatively low and probably ranges from about 0-8%, with concerns about technical errors in HR status determination by IHC often being expressed in this instance. Because of this, I would consider repeat receptor testing at some point (an additional b...